Biomecite gets option to GI-related IP from Univ. of MD, Baltimore
University of Maryland, Baltimore licensed Biomecite Diagnostics LLC an exclusive option to technology for use in developing diagnostics...
Tech Transfer Deals, June 2015
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced April through June 2015.
More from Deals
• By
Scrip discusses the latest M&A activity and trends with CEO Shawn Titcomb of Allele Capital and Cheryl Reicin, a partner focused on international life sciences activity at Mintz.
• By
The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.
• By
A deal last year with Sanofi relieved Novavax of commercial costs for the COVID-19 vaccine Nuvaxovid, allowing the company to focus on R&D and finding partners for its other vaccines.
• By
The Austrian firm is delisting from the NASDAQ and closing down.
More from Business
• By
The drugmaker plans to build a large manufacturing center in Virginia as the centerpiece of an effort to invest $50bn in the US by 2030.
• By
FDA issued a complete response letter to Replimune’s BLA for a novel oncolytic immunotherapy for melanoma in a surprise to management and investors.
• By
With drug sector indexes underperforming the broad market in the first half of 2025, investors may have been anticipating tariff-related and other headwinds. But impending loss of exclusivity on key products may be provoking more anxiety at this point.